Prime Medicine Inc PRME

$3.06 +0.18 (6.25%)

Valuation

Market cap
525,993,000
Revenue TTM
$4,630,000
Net income TTM
$-201,140,000
PE ratio
0.00
Forward PE
—
Profit margin
-4,344.28%
Debt to equity
0.00

Trading

Volume
1,268,655
Avg volume
2,891,028
Day's range
$2.88 – $3.03
Shares out
181,377,000
Stochastic %K
13%
Beta
2.34
Analysts
Strong Sell
Price target
$7.02

Price

Company profile

Prime Medicine, Inc., a biotechnology company, engages in delivering genetic medicines to address the spectrum of diseases by deploying gene editing technology in the United States. Its lead therapeutic product candidate is PM359 for Chronic Granulomatous Disease, which is in Phase 1/2 clinical trial; PM577 for Wilson Disease, that is in preclinical studies; and PM647 to treat genetic disorder caused by mutations in...

Show more

Prime Medicine, Inc., a biotechnology company, engages in delivering genetic medicines to address the spectrum of diseases by deploying gene editing technology in the United States. Its lead therapeutic product candidate is PM359 for Chronic Granulomatous Disease, which is in Phase 1/2 clinical trial; PM577 for Wilson Disease, that is in preclinical studies; and PM647 to treat genetic disorder caused by mutations in the SERPINA1 gene, resulting in production of misfolded Z-AAT protein that accumulates in the liver and leads to hepatocellular injury, cirrhosis, and increased risk of hepatocellular carcinoma. The company also provides vivo programs targeting diseases of the liver, and Cystic Fibrosis programs. In addition, it offers Prime Editing technology comprising a programmable DNA binding domains, such as Cas domains, are typically modified such that they do not cause a double-stranded break in the DNA, as well as a RT domain that copies the edited DNA sequence directly into the target genomic site where the edit is made; and pegRNA which contains a search sequence, also known as a spacer, which provides a target genomic address for the Prime Editor. The company has a research collaboration and license agreement with BMS; Cystic Fibrosis Foundation; Broad Institute; and Beam. Prime Medicine, Inc. was incorporated in 2019 and is headquartered in Cambridge, Massachusetts.

Industry
Biotechnology
Sector
Healthcare
Phone
617 465 0013
Website
https://primemedicine.com
Address
60 First Street, Cambridge, United States

Latest news

Stocktwits

LoveRetailFroth Sep 29, 2:57 PM
$SMMT Half hr craziness gone. Let’s go🚀 $RXRX $PRME $AMLX
0 replies
jschor88 Sep 29, 1:55 PM
$PRME in
0 replies
LoveRetailFroth Sep 28, 10:14 PM
$TSHA Nice day🍺 Loaded 50k shares in this & $PRME & 100k in $PRQR All 💎 s.
0 replies
TFars Sep 28, 8:00 PM
$PRME closed out before close
0 replies
TFars Sep 28, 6:10 PM
Spending time in my own head this morning. I broke two of my rules. I do this from time to time and usually the market punishes me for it. Rule one is don’t invest in BIOS or Apparel. Will be adding food to that don’t invest list. Rule 2 is don’t but swing positions during September or October. You’ll end up becoming a holder or taking a loss. Apologies to anyone looking at trades I make, will sell $PRME soon. Doesn’t mean I don’t think it’s not a good company. Your rules won’t be my rules. Respect your rules. It will allow for the conviction you’ll need to make money.
3 replies
PorkchopSquats Sep 28, 4:52 PM
$CRSP $PRME And this gets buried in a NYT pay-walled article. https://www.nytimes.com/2026/09/27/science/anthropic-biology-enzyme-mestre.html
2 replies
arg195 Sep 28, 4:15 PM
$PRME last Oct 😂. "Imagine shorting TSLA when the EV tax credits were announced" 😂😂😂
0 replies
ATTAB0Y Sep 28, 3:23 PM
$PRME https://hms.harvard.edu/news/new-gene-editing-method-prime-assembly-corrects-multiple-mutations-once
0 replies